Infectious diarrhea in children can be life-threatening and imposes a large economic burden on healthcare systems, therefore more effective prophylactic and therapeutic drugs are needed urgently. Because most of the pathogens responsible for childhood diarrhea infect the gastrointestinal mucosa, providing protective immunity at the mucosal surface is an ideal way to control pathogen invasion and toxic activity. Mucosal (e.g. oral, nasal) vaccines are superior to systemic (subcutaneous or intramuscular) vaccination for conferring both mucosal and systemic pathogenspecific immune responses. Therefore, great efforts has been focused on the development of cost-effective mucosal vaccines for the past 50 years. Recent progress in plant genetic engineering has revolutionized the production of inexpensive and safe recombinant vaccine antigens. For example, rice plant biotechnology has facilitated the development of a cold-chain-free rice-based oral subunit vaccine against Vibrio cholerae. Furthermore, this technology has led to the creation of a rice-based oral antibody for prophylaxis and treatment of rotavirus gastroenteritis. This review summarizes current perspectives regarding the mucosal immune system and the development of mucosal vaccines and therapeutic antibodies, particularly rice-based products, and discusses future prospects regarding mucosal vaccines for children.
Despite the general improvement in children's health worldwide, infectious diarrhea remains a major cause of death after pneumoniae in children younger than 5 years and >1 month of age. It accounts for 0.61 million deaths annually, which is approximately 16% of total deaths (3.2 million) in that population. 1 Childhood deaths attributable to diarrhea are predominant in developing countries, 1 whereas in developed countries, infectious diarrhea has a low mortality but causes a huge financial burden on health-care systems due to physician visits and hospitalizations. [2] [3] [4] In the USA, norovirus infection causes more than $273 m in treatment costs annually for hospitalizations (>14 000), emergency department visits (>281 000), and outpatient visits (>627 000) in children aged <5 years. 2 Therefore controlling infectious diarrhea for children is a great mission and challenge in both developed and developing countries. Because most of the pathogens responsible for childhood diarrhea deaths and hospitalizations, such as norovirus, rotavirus, Vibrio cholerae, enterotoxigenic Escherichia coli, and non-typhoidal Salmonella spp. infect the mucosal surface at the gastrointestinal tract, 5 bolstering the active or passive host defense against pathogens at the digestive mucosal surface is a rational strategy.
In order to provide the pathogen-specific active host defense, vaccines that effectively induce both mucosal and systemic acquired immunity are ideally required for the control of gastrointestinal infectious diseases. In this regard, there are two major options for vaccine treatment: systemic vaccination via i.m. or s.c. injection; and mucosal vaccination via the oral or nasal route. Injection-type vaccines induce a strong pathogen-or toxin-specific immunoglobulin (Ig)G antibody at the systemic compartment, whereas they are less effective in eliciting pathogen-specific protective immunity at the mucosal compartment. 6 In contrast, the delivery of vaccines across mucosal surfaces, such as by the oral or nasal route, effectively stimulates the mucosal immune system and provides pathogen-specific mucosal immune responses in addition to systemic immune responses, as described in the present review. 6 Therefore, like the currently approved oral vaccines against rotavirus and Vibrio cholerae, 7-9 most of current vaccine candidates against diarrheal pathogens were developed as mucosal (typically oral) vaccines to deliver antigen to mucosal inductive sites, such as Peyer's patches (PP), or to stimulate mucosal antigen-presenting cells (APC) such as dendritic cells (DC).
however, advances in antibody engineering and the discovery of the variable domain of heavy-chain antibodies (VHH), which constitutes the smallest antigen-binding domain associated with high binding capacity and pepsin-, acid-, and heatstable features, 16, 17 have accelerated the development of oral antibody fragments and thus interest in the concept of oral antibody prophylaxis and therapy. No oral antibody drugs are approved for human use currently, but anti-rotavirus VHH are to become antibody drug candidates in light of accumulated evidence regarding their efficacy in reducing diarrhea in mouse pups and in infants. [18] [19] [20] In addition to effectiveness, important aspects in getting mucosal vaccine and oral antibody drug to market are safety and low production cost. In this regard, plant-based protein production system can yield high quantities of recombinant proteins that are not contaminated with pathogens of animals or humans; these features enhance product safety and reduce production costs compared with those associated with conventional recombinant protein techniques using mammalian cells, bacteria, yeast, or baculovirus. 21 No plant-based products are licensed for human use currently, but rice-based recombinant protein technology, established in Japan, has been used to develop cold-chain-free oral vaccine and antibody drug candidates, 6 ,22-27 and a rice-based oral cholera vaccine is being prepared for phase II clinical trial aimed at obtaining approval for human use.
This review summarizes current perspectives of the mucosal immune system as it relates to the development of mucosal vaccines and antibody drugs, focusing on rice plant-based products that are already or expected to soon be under clinical trial, and discusses the future of mucosal vaccine development for children.
Mucosal immune system
Gastrointestinal surfaces are protected against pathogen invasion both specifically and non-specifically by physical, chemical and immunologic defense mechanisms (Fig. 1a) . One component of the non-specific defense system that protects against pathogen invasion is the physical barrier, which consists of epithelial cells covered with mucus. 28 Antimicrobial proteins, such as defensins and lysozymes, typically are produced by epithelial cells and kill or inactivate microorganisms by attacking the basic cell wall structures of bacteria. 29 Lactoferrin, a protein generally derived from breast milk, inhibits bacterial growth through iron-dependent and -independent mechanisms. 30 Pathogen-specific defense schemes rely on both cellular and humoral immunity. In terms of cellular immunity, mucosal cytotoxic T lymphocytes (CTL) are crucial for the immune clearance of pathogenesis. Pathogen-specific CTL typically are induced after the mucosal administration of live or attenuated pathogens or by using oral vaccine antigens with strong adjuvants such as cholera toxin (CT) or heat-labile enterotoxin (LT). Regarding humoral immunity, secretory IgA (sIgA) plays a key role in gut protection. The IgA found in serum typically is monomeric, whereas mucosally secreted IgA is dimeric or polymeric and is associated with the secretory component, which provides enzymatic resistance, thus effectively inhibiting pathogen invasion and toxin activity in the protease-containing gut lumen. 31 Gut-associated lymphoid tissue (GALT), which is predominantly composed of PP, isolated lymph nodules, and mesenteric lymph nodes, is critical for effectively inducing the production of antigen specific-sIgA.
Beneath the follicle-associated epithelium (FAE) of PP, APC such as DC, B cells, and T cells construct the immune networks that lead to the induction of acquired immunity and oral tolerance (Fig. 1a) . In the FAE, pathogens or oral-administered antigens are taken up by M cells, which form intraepithelial pockets specialized for the transepithelial transport of antigen. 32 Alternatively, antigens are taken up by intestinal villous M cells (Fig. 1a,b) . 33 In PP, APC beneath the M cells capture antigens, which are processed and then presented to CD4 + and CD8 + ab T cells. Activated T cells secrete the cytokines such as transforming growth factor (TGF-b) and interleukin (IL)-4 to promote class-switching of B cells to produce IgA (Fig.1b) . The cytokines secreted from mucosal T cells (IL-4 and TGF-b) and epithelial cells (TGF-b) cooperate to promote the maturation of IgA-producing B cells. Furthermore, intestinal DC-derived retinol, a metabolite of vitamin A, enhances the expression of a4b7 integrin and CC chemokine receptor 9 (CCR9) on T and B cells upon activation and imprints them with "gut-homing" specificity. 34, 35 Through gut-homing, the activated T and B cells migrate from PP through the efferent lymphatics to the regional mesenteric lymph nodes and then to the intestinal lamina propria by way of lymphatic ducts and blood circulation. 36 As just mentioned, the trafficking of activated B and T cells from the blood to the intestinal lamina propria (i.e. gut-homing) is regulated by interactions involving a4b7 integrin and CCR9 (Fig. 1b) . Small intestinal microvascular endothelial cells express mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), which binds to a4b7 integrin. In addition, endothelial cells release CC chemokine ligand 25 (CCL25), which bind to CCR9, its receptor for CCL25; therefore, activated B and T cells expressing a4b7 integrin and CCR9 are attracted to the lamina propria. 37, 38 In addition, epithelial cells also produce CCL25, further attracting immune cells to the lamina propria below the villous epithelium. In the presence of various cytokines, including IL-5 and IL-6, IgAcommitted B cells differentiate into IgA-producing plasma cells. Dimeric or polymeric IgA released from the plasma cells attaches to the polymeric immunoglobulin receptor (pIgR) located on the basolateral surface of mucosal epithelial cells, is transcytosed to the apical surface, and is then secreted into the mucus layer (Fig. 1c) . 31 During transcytosis, a portion of pIgR is cleaved off; the remaining portion stays attached to IgA and is therefore called the secretory component. Therefore, IgA, rather than IgG or IgM, is the predominant immunoglobulin isotype in most mucosal secretions. sIgA attaches to the pathogenic microorganisms and toxin and blocks their access to the mucosal epithelial cells.
Furthermore, M cell-mediated reverse transcytosis of antigensIgA complex contributes to the presentation and processing by the APC, leading to an adaptive immune response against the antigen.
Mucosal vaccines
According to our understanding of the mucosal immune system, vaccine antigens must be administered to mucosal inductive sites such as PP to induce mucosal-specific protective immunity. Consequently, systemic (i.m. s.c.) vaccination, which does not deliver antigen to mucosal inductive sites, is minimally effective in stimulating the mucosal immune system. In addition, the particular gut-homing system used is dependent on the mucosal site (i.e. gut or nasal) where the antigen is administered. Nasally administered vaccine antigens provide specific mucosal immunity predominantly in the respiratory tract, 36, 39, 40 but poorly induce specific sIgA in the gut. Therefore, the oral route is more appropriate for vaccination against diarrheal pathogens, compared with the nasal route. On this basis, the currently licensed vaccines against diarrheal diseases -inactivated whole-cell cholera vaccine (Shancholâ; Shantha Biotechnics, Hydrabad, India), inactivated whole-cell recombinant B subunit cholera (CTB) vaccine (Dukoralâ; Valneva, Lyon, France), and live attenuated rotaviral vaccines (Rotarixâ; GlaxoSmithKline Biologicals, Rixensart, Belgium; and RotaTeqâ; Merck, Riverside, PA, USA) -were developed as oral vaccines and effectively reduce pathogen-induced diarrhea in children. [7] [8] [9] 41 Conventional whole-cell or whole-virus vaccines, however, are costly in terms of the need to maintain a low-temperature supply chain (i.e. cold chain) and are associated with underlying risks for infectious contaminants or reversion to virulence (in the case of live attenuated vaccines). Therefore, there is a growing demand for improvements of existing vaccines in terms of improved cost-effectiveness, storage and safety.
During the late 1980s and early 1990s, progress in immunology, molecular biology, and recombinant gene technologies contributed to the development of new vaccine candidates based on the subunit principle, in which a pathogenic component is used as a vaccine antigen (e.g. the cholerae toxin B subunit, toxin-co-regulated pili of Vibrio cholerae, Helicobacter pylori urease, viral protein (VP)4 and VP7 rotavirus capsid protein antigens). [42] [43] [44] [45] [46] These recombinant vaccine antigens, however, have several drawbacks. First, these antigens are easily digested by gastric acid, which hampers their delivery to mucosal inductive sites (i.e. PP). Second, these recombinant antigens are less immunogenic than are wholecell vaccines. Third, conventional recombinant protein production methods using bacteria, yeast, or mammalian cells are costly in terms of production and purification; furthermore, the products are associated with a risk of infectious contaminants.
To resolve these problems, the development of mucosal vaccines focused on (i) drug-delivery systems, which protected vaccine antigens from degradation by gastric acids or delivered the antigen directly to the immune-inductive tissue (such as PP) or M cells; (ii) adjuvants, to stimulate the acquired immune system by activating immune cells (mainly DC); and (iii) production systems that produced vaccine antigen at low cost and without infectious contaminants.
In regard to drug-delivery systems, an M cell-targeting vaccine using anti-M cell specific antibody, 47 a microcapsule vaccine promoting effective antigen uptake by M cells, 48 and a rice-based vaccine that escapes protease-mediated degradation have been developed. 22 In addition, mucosal adjuvants including enterotoxins, CT, and LT have been shown to induce strong antigen-specific immune responses, 10, 11, 49 but these enterotoxins cannot be used in humans because of their toxicity. Therefore, various alternative mucosal adjuvants, including non-toxic mutant CT or LT, CTB, and toll-like receptor (TLR) agonists that target pattern recognition receptors on DC, have been studied. 10, 11, 50 Another important aspect to resolve regarding mucosal vaccine development is the cost-effective production of vaccine antigen. Since the late 1990s, plant genetic engineering has made it possible to produce vaccine antigen protein in plants, including rice, tobacco, maize, potato, lettuce, and carrot. 22, [51] [52] [53] [54] [55] [56] Plants yield high amounts of recombinant proteins that are free of contamination by animal or human pathogens. 21 Most of the plants used for protein synthesis have been edible plants (e.g. rice, potato, lettuce); thus, plant biotechnology has led to the concept of edible vaccines, which eliminate the costs associated with protein purification. In addition, when given orally, plant-based antigens can induce both mucosal and systemic immune responses to provide protection against pathogen-induced diarrhea. 22, [51] [52] [53] [54] [55] [56] Because vaccine price, including the costs and methods of vaccine storage, delivery, and treatment route (e.g. needles, syringes), can limit the ability of a country (especially developing countries) to immunize its population, plant-based pharmaceuticals hold great promise for bringing cost-effective and safe vaccines to market.
Rice-based vaccines
Rice is an attractive candidate antigen-expressing plant for vaccine production because rice seed is suitable for long-term preservation of antigen protein without the need of a cold chain (i.e. refrigerated storage), and it is resistant to digestion by gastric acids. Professor Hiroshi Kiyono and Dr Yoshikazu Yuki (Division of Mucosal Immunology, Institute of Medical Science, University of Tokyo) used the unique biologic characteristics of rice seed to devise a new vaccine production, preservation, and delivery system (Fig. 2) . 6, 22 Agrobacterium tumefaciens naturally infects and introduces its transfer DNA (T-DNA) region into plants. Using this characteristic, the T-DNA region of A. tumefaciens can be replaced with a vaccine antigen gene, which subsequently is introduced into the rice callus, a mass of undifferentiated rice plant cells. Once a transgenic line that stably produces the target protein is established, it can be used as a permanent source of vaccine antigen and established as a master seed bank. Using the method described, we created a plant-based anti-cholera vaccine by expressing the CTB subunit in rice (Fig. 2) . 6, 22 In cholera, V. cholerae-producing CT, which consists of a dimeric A subunit (CTA) and pentameric CTB, causes diarrhea. CTB, the non-toxic component of CT, binds to intestinal epithelial cells by means of the GM1 receptor. 57 After CT is endocytosed, CTA is released, consequently inhibiting the uptake of sodium chloride by villi and stimulating active chloride secretion by crypt cells; together these effects cause severe diarrhea and fluid loss. 57 Therefore, using anti-CTB sIgA antibody to inhibit CTB from binding to the GM1 receptor might prevent diarrhea or reduce its severity (Fig. 2) .
According to this concept, use of an Agrobacteriummediated method to transduce the gene encoding CTB into rice seed achieved an average of 30 lg recombinant CTB protein per transgenic rice seed, thus characterizing this system as a high-protein antigen production system. 22 In addition, recombinant CTB accumulated in the rice protein body (PB), which protected the CTB from pepsin digestion, suggesting that the rice PB acts as a natural capsule for oral vaccine treatment. 22 Furthermore, oral immunization of mice with rice-based CTB elicited CTB-specific serum IgG and intestinal IgA antibodies and protected the animals from CT-induced diarrhea (Fig. 2) . 6, 22 In an experiment in pIgR-deficient mice, which lack the production and transepithelial transport of sIgA, intestinal CTB-specific sIgA, not serum IgA or IgG, was responsible for humoral protective immunity against CT-induced diarrhea. 6 This indicates that rice-based CTBinduced sIgA played a critical role in providing protection against CT-induced diarrhea. In addition, oral immunization with rice-based CTB that had been stored at room temperature for >3 years induced CTB-specific serum IgG and intestinal sIgA responses at the same levels as those induced by freshly harvested rice-based CTB in mice. 6 This suggests that a major advantage of this system is that the vaccine can be stored for long periods without the need for a cold chain, which will be a particular advantage in developing countries. As a step toward using rice-based CTB in humans, it has been confirmed that vaccination with MucoRice-CTB induces CTB-specific sIgA without adverse effects in non-human primates (i.e. Macaca fascicularis). 27 In addition, because the amino acid sequence and protein conformation of CT are similar to those of the LT produced by enterotoxigenic Escherichia coli (ETEC), the cause of travelers' diarrhea, rice-based CTB likely will be effective against ETEC-induced diarrhea. Rice-based CTB has also shown effectiveness in protection against ETEC-induced diarrhea in mice and pigs. 6, 25 In 2006, a tobacco-based vaccine against Newcastle disease virus was the first plant-based vaccine approved by the US Department of Agriculture for veterinary use. 58 The effectiveness of the rice-based vaccine against pig ETEC may accelerate the veterinary use of rice-based CTB prior to its use in humans. Only a few plant-based vaccines have reached human clinical trials. [59] [60] [61] [62] For example, the safety and immunogenicity of potato-and maize-based oral vaccines expressing LTB against ETEC were confirmed in clinical trials, in which LTB-specific serum IgG and IgA were induced in healthy adult volunteers. 59 In addition, norovirus capsid protein VP1 produced in potato tubers was given orally to healthy volunteers, and 20% of vaccinated volunteers developed VP1-specific serum IgG titers. 60 Following the effectiveness of the rice-based oral cholera vaccine in protecting against diarrhea, a vaccine production system was developed and the produced vaccine was thoroughly characterized in accordance with the governmental regulatory requirements. [63] [64] [65] [66] The rice-based CTB vaccine has been extensively characterized by whole-genome sequencing, proteome analyses, and metabolome analysis. 64, 66 The master seed bank was established, and the rice-based vaccine is produced in a closed cultivation system to minimize variations in antigen expression and quality during vaccine manufacture. 63 Recent analysis has confirmed that CTB expression in rice seed does not upregulate known rice allergens. 65 Finepowdered rice-based vaccine was evaluated in a physicianinitiated phase I study at the Research Hospital of the Institute of Medical Science (University of Tokyo). Further details of this phase I study will be published elsewhere. Due to collaboration with a pharmaceutical company, the rice-based CTB vaccine is preparing for phase II clinical testing aimed at securing approval for the use of the vaccine in humans.
Oral antibody drugs
As a natural source of passive immunity, IgA antibodies against V. cholerae and Campylobacter jejuni in breast milk protected breast-fed children against those pathogen-induced diarrheas. 67, 68 As another way to confer specific passive immunity, oral and intestinal inoculation of monoclonal antibodies against rotavirus capsid protein reduced the severity of rotavirus-induced disease in mice. 12, 13 In humans, oral treatment with bovine milk hyper-immunized using rotavirus showed effectiveness in reducing rotavirus-induced diarrhea in children. 14, 15 Therefore, oral treatment with antibodies as drugs is an attractive strategy for preventing and treating infectious diarrhea. Several problems, however, have hampered the practical use of oral antibody drugs: the antibody Fig. 2 Schema of rice-based oral cholera vaccine production. The cholera toxin B subunit (CTB) gene of V. cholerae was inserted into a transfer DNA (T-DNA) plasmid with endosperm specific promotor. The resulting T-DNA plasmid was transformed in the rice callus, a mass of undifferentiated rice plant cells, using an Agrobacterium-mediated method. Seeds of rice plants, which were regenerated from the transformed rice calluses, expressed CTB (30 lg/seed). Oral immunization of mice with rice-based CTB elicited CTB-specific serum immunoglobulin (Ig)G and intestinal secretory IgA (sIgA) antibodies and protected the animals from cholera toxin (CT)-induced diarrhea via mucosal CTB-specific sIgA-mediated inhibition of CT binding to epithelial cells. In addition, oral immunization with rice-based CTB that had been stored at room temperature for >3 years induced CTBspecific serum IgG and intestinal sIgA responses at the same levels as those induced by freshly harvested rice-based CTB in mice. CTA, cholera toxin A subunit. production and purification processes are costly, and oral purified antibody proteins are easily degraded by gastric and intestinal proteases. In 1993, a pepsin-, acid-, heat-stable antibody was discovered: the variable domain of camel heavychain antibodies (VHH), which do not possess light chains, constitutes the smallest antigen-binding domain associated with high binding capacity (Fig. 3) . 16 In addition, the expression of VHH antibody fragments in microorganisms was similar to that of conventional antibody fragments (antigen-binding fragment [Fab] and single-chain fragment variable [ScFv]); 17 consequently VHH antibody technology has rapidly progressed. Oral inoculation of yeast-derived recombinant llama VHH antibody fragments against rotavirus (anti-rotavirus protein [ARP]1) decreased rotavirus-induced diarrhea in mouse pups. 18 Lactobacilli producing ARP1 were generated and shown to be effective in the same mouse pup model. 19 Furthermore, oral ARP1 produced by yeast safely and effectively reduced the severity of rotavirus-induced diarrhea in children in a phase II clinical trial conducted in Bangladesh. 20 The anti-rotavirus VHH are expected to achieve approval for human use.
Rice-based antibody drug
To produce VHH antibody fragments cost-effectively, plant biotechnology was able to successfully produce VHH in rice, tobacco, and Arabidopsis thaliana. 23, 69, 70 In collaboration with colleagues at the Karolinska Institute, we combined our ricebased biotechnology with VHH technology and successfully developed rice seed that expresses ARP1.
23 ARP1, combined with an RNA interference (RNAi) suppression cassette, was transfected into rice plants using A. tumefaciens-mediated transformation (Fig. 3) . 23 Through RNAi technology, the production of rice storage proteins (prolamin and glutelin) was suppressed in the transgenic rice seed, and ARP1 predominantly expressed (Fig. 3) . Uniquely, simply mixing water with powdered transgenic rice seed released the rice-based ARP1 as a soluble form, thus achieving a purification-free production process. Furthermore, this methodology achieved an average of 170 lg soluble ARP1 per seed, representing 11.9% of the total seed protein. In comparison with previous plant-based antibodies (scFV, IgG, Fab, and VHH), [71] [72] [73] [74] the rice-based production system achieved an extremely high yield of soluble antibodies. In addition, rice-derived ARP1 neutralized the human rotavirus strains Wa G1P [8] , ST-3 G4P [6] , 69M G8P [10] , F45 G9P [8] , and Va70 G4P [8] . 23 The outer-layer proteins of rotavirus, VP7 and VP4, both contain neutralizing epitopes, although these tend to be serotype specific. 75 In contrast, the middle-layer protein, VP6, is the most abundant and immunodominant VP, contains groupand subgroup-determining epitopes, and is recognized by ARP1. 75 Therefore, rice-based ARP1 likely provides a broad neutralizing capacity. Furthermore, oral rice-based ARP1 markedly decreased the viral load in immunocompetent as well as immunodeficient mice. 23 Rice-based ARP1 retained in vitro neutralizing activity after long-term storage (>1 year) and boiling, and conferred protection in mice even after heat treatment at 94°C for 30 min (Fig. 3) . 23 High-yield, watersoluble, and purification-free rice-based ARP1 thus forms the basis for oral prophylaxis and therapy against rotaviral infection.
In the phase II clinical trial evaluating yeast-derived ARP1, 6-24-month-old children with rotaviral diarrhea received ARP1 at 15-30 mg/kg daily, 18 which is equivalent to 88-176 seeds of rice-based ARP1/kg daily. When the rice-based ARP1 is used for those children in the future, ARP1-containing supernatant of the rice water will be given orally. Rice-based ARP1 represents an approach to the prevention and treatment of rotavirus-induced diarrhea that can reduce the medical and economic burden of the disease in both developed and developing countries and complement current vaccine-based Fig. 3 Schema of rice-based oral antibody production. In addition to conventional antibodies (with heavy and light chains), camelids (e.g. camels, llamas) also produce antibodies with solely the heavy chain. The variable domain of heavy chain of heavychain antibody (VHH) has binding properties. An anti-rotavirus protein 1 (ARP1), which is a rotavirus-specific VHH, was selected from a library of VHH fragments generated from llamas immunized with rhesus rotavirus (G3). The gene encoding ARP1 was synthesized with an optimized codon usage for plants and inserted into a binary transfer DNA (T-DNA) vector. This vector contains a cassette for overexpression of ARP1 and a combination cassette for RNA interference (RNAi) suppression of production of the major rice endogenous storage proteins, prolamin and glutelin. The plasmid was transformed into a rice plants, using an Agrobacterium-mediated method. The expression of the prolamin and glutelin was suppressed and the ARP1 protein was predominantly expressed in the transgenic rice. The ARP1 solution extracted from the rice-based ARP1 effectively reduced rotavirusinduced diarrhea in neonatal pups. Rice-based ARP1 retained in vitro neutralizing activity after long-term storage (>1 year) and boiling, and conferred protection in mice even after heat treatment at 94°C for 30 min. CH, constant domain of the heavy chain; CL, constant domain of the light chain; VH, variable domain of the heavy chain; VL, variable domain of the light chain.
prophylaxis, in situations where live attenuated vaccines are contraindicated. Furthermore, rice-based ARP1 does not upregulate known rice allergens, thus indicating it as a potentially safe oral antibody for clinical application. 76 Future perspectives of mucosal vaccine and antibody drug development Effective mucosal vaccines and antibody drugs are urgently needed for life-threatening diarrheal pathogens for which licensed vaccines are currently unavailable. In this regard, norovirus is a leading cause of virus-induced childhood diarrhea, but an approved noroviral vaccine is unavailable currently, largely due to the lack of an established system for culturing human norovirus. Current norovirus vaccine candidates therefore have used virus-like particles (VLP) as a vaccine antigen. Because recombinant VLP are digested by gastric acid, injectable and nasal vaccines have been manufactured and are reported to induce serum-specific IgA, 77 activate antibodysecreting memory B cells 78 and effectively reduce diarrhea in healthy adults, 79, 80 but their efficacy in children is undetermined as yet. Compared with adults, children have less exposure to norovirus gastroenteritis, and thus fewer specific memory B cells; consequently vaccine efficacy must be carefully evaluated in children. Efforts to develop plant-based vaccine expressing VLP, including a rice-based product, are ongoing, and additional mucosal VLP vaccine research focusing on developing antigen-delivery systems and mucosal adjuvants is underway. [81] [82] [83] Otherwise, a recent successful cultivation of human norovirus in enterocytes in stem-cellderived human intestinal enteroids may lead to the development of a live-attenuated norovirus vaccine. 84 Alternatively, oral antibody drugs against norovirus are under development and are expected to offer alternatives for the prevention and treatment of noroviral gastroenteritis. 85 Another future perspective is the development of mucosal adjuvants for children. Neonates and infants are more susceptible to infection and tend to have more severe infection outcomes than do older children and healthy adults. 1, [86] [87] [88] In addition, infants need more vaccinations than do adults. 7, [89] [90] [91] These characteristics of susceptibility and poor immune induction may underlie the immature innate immunity in neonates and infants. In previous studies using cord blood, which is known to reflect neonatal immunity, the TLR-mediated innate immune response was impaired in neonates compared with adults. [92] [93] [94] [95] These findings prompted the concept of mucosal vaccines that use adjuvants specialized for children to stimulate the immature innate immune system of this population. We recently found that zymosan, a cell-wall extract from Saccharomyces cerevisiae that is composed mainly of b-glucan, is a TLR2 agonist that induces inflammatory immune responses in the monocytes, DC, and monocyte-derived DC of human cord blood similar to those in adult blood; 96 zymosan is thus likely to be an effective adjuvant in the induction of protective immunity in small children. In addition, the neonatal immune response is influenced by several maternal factors, 97 and further studies are attempting to identify appropriate mucosal adjuvants for children.
In conclusion, the mucosal immune system is a unique network that incorporates GALT, sIgA, gut-homing specificity, and so on, and that is separate from the systemic immune system. Based on our understanding of the mucosal immune system and advanced technologies such as plant biotechnology and antibody engineering, cost-effective and safe mucosal vaccines and oral antibody drugs against childhood diarrhea are being developed. Rice-based vaccines and antibody drugs are cold-chain free, purification free, and high yield; are ready for evaluation in clinical trials; and are expected to be the keys to overcoming childhood diarrhea.
